Abstract:BACKGROUND:Noonan syndrome (NS) is a multisystemic developmental disorder characterized by common, clinically variable symptoms, such as typical facial dysmorphisms, short stature, developmental delay, intellectual disability as well as cardiac hypertrophy. The underlying mechanism is a gain-of-function of the RAS-mitogen-activated protein kinase signaling pathway. However, our understanding of the pathophysiological alterations and mechanisms, especially of the associated cardiomyopathy, remains limited and effective therapeutic options are lacking.METHODS:Here, we present a family with two siblings displaying an autosomal recessive form of NS with massive hypertrophic cardiomyopathy as clinically the most prevalent symptom caused by biallelic mutations within the leucine zipper-like transcription regulator 1 (LZTR1). We generated induced pluripotent stem cell-derived cardiomyocytes of the affected siblings and investigated the patient-specific cardiomyocytes on the molecular and functional level.RESULTS:Patients' induced pluripotent stem cell-derived cardiomyocytes recapitulated the hypertrophic phenotype and uncovered a so-far-not-described causal link between LZTR1 dysfunction, RAS-mitogen-activated protein kinase signaling hyperactivity, hypertrophic gene response and cellular hypertrophy. Calcium channel blockade and MEK inhibition could prevent some of the disease characteristics, providing a molecular underpinning for the clinical use of these drugs in patients with NS, but might not be a sustainable therapeutic option. In a proof-of-concept approach, we explored a clinically translatable intronic CRISPR (clustered regularly interspaced short palindromic repeats) repair and demonstrated a rescue of the hypertrophic phenotype.CONCLUSIONS:Our study revealed the human cardiac pathogenesis in patient-specific induced pluripotent stem cell-derived cardiomyocytes from NS patients carrying biallelic variants in LZTR1 and identified a unique disease-specific proteome signature. In addition, we identified the intronic CRISPR repair as a personalized and in our view clinically translatable therapeutic strategy to treat NS-associated hypertrophic cardiomyopathy.

Cardiac Phenotype and Gene Mutations in RASopathies

Cardiac Manifestations and Associations with Gene Mutations in Patients Diagnosed with RASopathies

Clinical and mutation profile of pediatric patients with RASopathy-associated hypertrophic cardiomyopathy: results from a Chinese cohort

New Insights Into the Spectrum of RASopathies: Clinical and Genetic Data in a Cohort of 121 Spanish Patients

[New Insight of Craniofacial and Oral Findings of the RASopathies].

[Advances in the Molecular Pathogenesis of Hypertrophic Cardiomyopathy].

Activating Mutations Affecting the Dbl Homology Domain of SOS2 Cause Noonan Syndrome

Co-Mutation Landscape and Clinical Significance of RAS Pathway Related Gene Mutations in Patients with Myelodysplastic Syndrome

RAF-1 Mutation Associated with a Risk for Ventricular Arrhythmias in a Child with Noonan Syndrome and Cardiovascular Pathology

Intronic CRISPR Repair in a Preclinical Model of Noonan Syndrome-Associated Cardiomyopathy.

Noonan Syndrome: Relation of Genotype to Cardiovascular Phenotype—A Multi-Center Retrospective Study

Skeletal defects and bone metabolism in Noonan, Costello and cardio-facio-cutaneous syndromes

The Cardiofaciocutaneous Syndrome: From Genetics to Prognostic-Therapeutic Implications

Biomarker Landscape in RASopathies

RASopathies for Radiologists

Natural history and outcomes in paediatric RASopathy‐associated hypertrophic cardiomyopathy

Neurodevelopmental Aspects of RASopathies

Noonan syndrome patient-specific induced cardiomyocyte model carrying SOS1 gene variant c.1654A>G

Developmental effect of RASopathy mutations on neuronal network activity on a chip

RASopathies Due to De Novo Pathogenic Variants: Clinical Features, Genetic Findings and Outcomes in Nine Neonates Born with Congenital Heart Defects

Targeting RAS mutants in malignancies: successes, failures, and reasons for hope